Kevin Brodbeck - Deciphera Pharmaceuticals Senior Officer
| DCPHDelisted Stock | USD 13.32 0.36 2.63% |
Executive
Kevin Brodbeck is Senior Officer of Deciphera Pharmaceuticals LLC
| Phone | 781 209 6400 |
| Web | https://www.deciphera.com |
Deciphera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2662) % which means that it has lost $0.2662 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5037) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Deciphera Pharmaceuticals LLC currently holds 25.88 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Deciphera Pharmaceuticals has a current ratio of 5.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Deciphera Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sandra Coombs | Alkermes Plc | N/A | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Thomas Rowland | ANI Pharmaceuticals | 57 | |
| Dimitri Grigoriadis | Neurocrine Biosciences | 66 | |
| Jennifer PharmD | Avadel Pharmaceuticals PLC | N/A | |
| Kevin Esq | Supernus Pharmaceuticals | 62 | |
| Jeff Bozick | Supernus Pharmaceuticals | N/A | |
| Ronald Silver | Ironwood Pharmaceuticals | 41 | |
| Jerad Seurer | Avadel Pharmaceuticals PLC | 51 | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| Camilo Camacho | Procaps Group SA | 50 | |
| Gabriele Hansen | Evotec SE ADR | N/A | |
| Monika Conradt | Evotec SE ADR | N/A | |
| Matthew CPA | Neurocrine Biosciences | 44 | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
| Todd MBA | Supernus Pharmaceuticals | N/A | |
| Samuel Parisi | Alkermes Plc | 49 | |
| MD MBA | Supernus Pharmaceuticals | 63 | |
| Kyle Gano | Neurocrine Biosciences | 51 | |
| Ingrid Delaet | Neurocrine Biosciences | 58 | |
| Aurelie Dalbiez | Evotec SE ADR | 47 | |
Management Performance
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 |
Deciphera Pharmaceuticals Leadership Team
Elected by the shareholders, the Deciphera Pharmaceuticals' board of directors comprises two types of representatives: Deciphera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Deciphera. The board's role is to monitor Deciphera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Deciphera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Deciphera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Flynn, Founder, Chief Scientific Officer | ||
| Daniel Martin, Chief Commercial Officer | ||
| Margarida Duarte, Senior International | ||
| Stephen Ruddy, VP Officer | ||
| Kevin Brodbeck, Senior Officer | ||
| Lisa Price, Senior Officer | ||
| Matthew MD, Executive Officer | ||
| Jeffrey JD, Senior Counsel | ||
| Steven Hoerter, President CEO | ||
| Dashyant Dhanak, Executive Officer | ||
| Thomas JD, CFO VP | ||
| Jennifer Larson, Senior Relations | ||
| Jama Pitman, Quality Regulatory |
Deciphera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Deciphera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |